XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Compensation Expense and Share-based Payment Plans
6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
8. Stock Compensation Expense and Share-based Payment Plans

Stock compensation expense was $181,511 and $210,427, and $376,955 and $425,775, for the three- and six-month periods ended June 30, 2018 and 2017, respectively.

 

As of June 30, 2018, the unrecognized stock-based compensation cost related to stock option awards and unvested restricted common stock was $1,157,000.  Such amount, net of estimated forfeitures, will be recognized in operations through the first quarter of 2022.

 

The following table summarizes the Company's stock option information as of and for the six-month period ended June 30, 2018:

 

          Weighted-     Aggregate     Weighted-Average  
    Option     Average     Intrinsic     Contractual Life  
    Shares     Exercise Price     Value (1)     Remaining in Years  
                         
Outstanding at December 31, 2017     3,573,250     $ 1.83     $ 31,968       5.9  
Granted     15,000       0.74       300          
Cancelled or expired     (297,500 )     2.53       —          
Exercised     —       —       —          
Outstanding at June 30, 2018     3,290,750       1.76       987,720       5.6  
Exercisable at June 30, 2018     2,491,375     $ 1.96     $ 337,558       4.7  
Vested and expected to vest at June 30, 2018     3,266,768     $ 1.77     $ 968,215       5.5  

 

 

(1) The intrinsic value of a stock option is the amount by which the market value of the underlying stock, as of the applicable date, exceeds the option exercise price.

 

 

The exercise period for all outstanding stock options may not exceed ten years from the date of grant.  Stock options granted to employees typically vest over a four-year period.  The Company attributes stock-based compensation cost to operations using the straight-line method over the applicable vesting period.

 

On June 20, 2018, the Company's stockholders approved the CAS Medical Systems, Inc. 2018 Equity Incentive Plan (the "Plan").  The maximum number of shares of common stock that may be granted under the Plan is 2,500,000.  Awards that may be granted under the Plan include options, restricted stock and restricted stock units, and other stock-based awards. The purposes of the Plan are to make available to our key employees and directors certain compensatory arrangements related to growth in value of our stock so as to generate an increased incentive to contribute to the Company's financial success and prosperity; to enhance the Company's ability to attract and retain exceptionally qualified individuals whose efforts can affect the Company's financial growth and profitability; and to align, in general, the interests of employees and directors with the interests of our stockholders.  As of June 30, 2018, there remained a total of 2,569,812 shares available for issuance, including 69,812 shares remaining under the 2011 Equity Incentive Plan.

 

On March 6, 2018, members of the management team, in lieu of cash payments, were granted 162,085 shares of vested common stock in connection with the achievement of certain 2017 management incentive targets.  The shares were valued at $1.10 each, based upon the Nasdaq official closing price of the Company's common stock on the date of issuance.

 

As of June 30, 2018, there were 968,812 outstanding restricted shares at a weighted-average fair value of $1.39 per share.  Included in this total are 150,000 shares of restricted common stock issued to the Company's Chief Executive Officer ("CEO") during August 2010.  The vesting of these shares granted to the Company's CEO is based upon certain stock price performance criteria that have not yet been met. The fair value of the outstanding restricted common shares has been calculated based upon the market value of the common stock as of the date of issuance. Restricted stock granted to employees typically vests over a period of not less than three years, while restricted stock granted to outside members of the Board of Directors typically vests over a period of not more than two years from date of grant.

 


 A summary of the unvested restricted shares of common stock outstanding follows:

 

    Six Months     Weighted-Average  
    Ended     Grant Date  
    June 30, 2018     Fair-Value  
             
Outstanding at beginning of period     1,107,250     $ 1.42  
Granted     —       —  
Cancelled     —       —  
Vested     (138,438 )     1.62  
Outstanding at end of period     968,812     $ 1.39  

 

 

Warrants to purchase 472,782 shares of common stock at a weighted-average exercise price of $1.39 per share were outstanding as of June 30, 2018. The warrants have an exercise price range of $0.38 to $1.98 per share, and warrants underlying 75,000 shares of common stock have no expiration date.

 

Warrants outstanding as of June 30, 2018, include a warrant granted to East West Bank in connection with the Company's Loan Agreement executed on May 8, 2018.  That warrant provides for the right to purchase an aggregate of 218,914 shares of the Company's common stock for a five-year period, expiring on May 8, 2023, at an exercise price of $1.142 per share.

 

As of June 30, 2018, there were 95,500 shares of Series A Convertible Preferred Stock and 54,500 shares of Series A Exchangeable Preferred Stock issued in connection with a 2011 private placement (collectively, the "Preferred Stock"), outstanding.  The Preferred Stock has a par value of $0.001 per share and is convertible into common stock of the Company at a price of $2.389 per share.  The Company can force conversion of all of the outstanding Preferred Stock if the closing price of its common stock meets certain share price, trading volume requirements, and other conditions.  The stated value ($100 per share) of the Series A Preferred Stock accretes at an annual rate of 7% compounded quarterly.  While such accretion may be paid in cash at the Company's option, the Company's current loan agreement prohibits the payment of cash dividends.  As of June 30, 2018, dividend accretion of $9,540,623 had accumulated on the Preferred Stock. The Preferred Stock is entitled to a liquidation preference equal to the greater of 100% of the total accreted value for each share of Preferred Stock, outstanding on the date of a liquidation, plus all accrued and unpaid dividends, or the amount a holder would have been entitled to had the holder converted the shares of Preferred Stock into common stock immediately prior to the liquidation.  Accordingly, based upon the liquidation value of the Preferred Stock at June 30, 2018, there were 10,272,341 shares of common stock issuable upon conversion of the Preferred Stock.  The Preferred Stock votes together with the common stock as if converted on the original date of issuance.  Holders of Preferred Stock are entitled to purchase their pro rata share of additional stock issuances in certain future financings.